Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

DROPLET

- PMLiVE

Novo Nordisk announces positive results for CagriSema in type 2 diabetes

CagriSema improved weight loss and blood glucose control compared to semaglutide alone across all tested doses

- PMLiVE

AstraZeneca and CSPC Pharmaceuticals enter collaboration on weight management therapies

Almost three billion people globally are thought to be either overweight or obese

- PMLiVE

NHS programme to give head and neck cancer patients fast-track access to mRNA vaccine

More than 11,000 people are diagnosed with head and neck cancers every year in England

Navigating NHS Market Access: Policy Change and Opportunity in England With Sarah Everest Ford

Navigating NHS Market Access: Policy Change and Opportunity in England

With the changes at NHS England and the publishing of the 10-Year Plan, there is a lot of talk of change in the NHS in England. But what do these...

Petauri Evidence

- PMLiVE

Eli Lilly’s Mounjaro shown to provide cardiovascular protection in type 2 diabetes patients

Approximately 38.4 million people in the US are affected by diabetes

- PMLiVE

Digital Transformation in the NHS’s 10-Year Plan: Techno-Optimism and the Limits of Efficiency

Here, Evelyne Priestman (Senior Consultant – HEOR) and Mary Baker (Senior Medical Writer) at Petauri Evidence explore the National Health Service (NHS) in England’s newly unveiled 10-year plan through the...

Petauri Evidence

- PMLiVE

Eli Lilly shares promising phase 3 results for once-weekly insulin candidate efsitora alfa

The company is planning to submit regulatory applications for the candidate by the end of the year

- PMLiVE

Live Q&A: Beyond NHS England – Navigating changes at NHSE and DHSC

What impact can we expect from the abolition of NHS England (NHSE) and changes at the Department of Health and Social Care (DHSC)? What do these changes mean for your...

Petauri Evidence

- PMLiVE

Novo Nordisk gains rights to United Laboratories’ triple receptor agonist in deal worth $2bn

UBT251 is in early-stage clinical development for type 2 diabetes, obesity and other diseases

- PMLiVE

Live Q&A: Beyond NHS England – Restructuring and its implications for Pharma and Medtech

What does the abolition of NHS England mean for your market access and NHS Engagement strategy? How will the changes at national and integrated care board (ICB) level impact launch...

Petauri Evidence

- PMLiVE

Novo shares phase 3 results for obesity candidate CagriSema in diabetes patients

The company is expecting to file for the first regulatory approval of the drug next year

- PMLiVE

The abolition of NHS England: Navigating NHS restructuring and its impact on the pharmaceutical industry

Last week Prime Minister Sir Keir Starmer announced the abolition of NHS England to "cut bureaucracy" and bring management of the health service "back into democratic control". This significant change...

Petauri Evidence

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links